Compare RWAY & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RWAY | RNAC |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | 75 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.7M | 243.0M |
| IPO Year | N/A | 2016 |
| Metric | RWAY | RNAC |
|---|---|---|
| Price | $6.34 | $6.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $9.50 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 700.1K | 149.1K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 21.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,797,000.00 |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | $5.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.22 | $5.60 |
| 52 Week High | $11.41 | $14.56 |
| Indicator | RWAY | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 43.02 |
| Support Level | N/A | $6.07 |
| Resistance Level | $6.97 | $6.60 |
| Average True Range (ATR) | 0.21 | 0.69 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 15.53 | 16.89 |
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.